In a mouse mutagenesis screen, we isolated a mutant, Myshkin ( Myk ), with autosomal dominant complex partial and secondarily generalized seizures, a greatly reduced threshold for hippocampal seizures in vitro, posttetanic hyperexcitability of the CA3-CA1 hippocampal pathway, and neuronal degeneration in the hippocampus. Positional cloning and functional analysis revealed that Myk /+ mice carry a mutation (I810N) which renders the normally expressed Na + ,K + -ATPase α3 isoform inactive. Total Na + ,K + -ATPase activity was reduced by 42% in Myk /+ brain. The epilepsy in Myk /+ mice and in vitro hyperexcitability could be prevented by delivery of additional copies of wild-type Na + ,K + -ATPase α3 by transgenesis, which also rescued Na + ,K + -ATPase activity. Our findings reveal the functional significance of the Na + ,K + -ATPase α3 isoform in the control of epileptiform activity and seizure behavior.
24 October 2011 in Proceedings of the National Academy of Sciences
Bipolar disorder is a debilitating psychopathology with unknown etiology. Accumulating evidence suggests the possible involvement of Na + ,K + -ATPase dysfunction in the pathophysiology of bipolar disorder. Here we show that Myshkin mice carrying an inactivating mutation in the neuron-specific Na + ,K + -ATPase α3 subunit display a behavioral profile remarkably similar to bipolar patients in the manic state. Myshkin mice show increased Ca 2+ signaling in cultured cortical neurons and phospho-activation of extracellular signal regulated kinase (ERK) and Akt in the hippocampus. The mood-stabilizing drugs lithium and valproic acid, specific ERK inhibitor SL327, rostafuroxin, and transgenic expression of a functional Na + ,K + -ATPase α3 protein rescue the mania-like phenotype of Myshkin mice. These findings establish Myshkin mice as a unique model of mania, reveal an important role for Na + ,K + -ATPase α3 in the control of mania-like behavior, and identify Na + ,K + -ATPase α3, its physiological regulators and downstream signal transduction pathways as putative targets for the design of new antimanic therapies.
Missense mutations in ATP1A3 encoding Na+,K+-ATPase α3 have been identified as the primary cause of alternating hemiplegia of childhood (AHC), a motor disorder with onset typically before the age of 6 months. Affected children tend to be of short stature and can also have epilepsy, ataxia and learning disability. The Na+,K+-ATPase has a well-known role in maintaining electrochemical gradients across cell membranes, but our understanding of how the mutations cause AHC is limited. Myshkin mutant mice carry an amino acid change (I810N) that affects the same position in Na+,K+-ATPase α3 as I810S found in AHC. Using molecular modelling, we show that the Myshkin and AHC mutations display similarly severe structural impacts on Na+,K+-ATPase α3, including upon the K+ pore and predicted K+ binding sites. Behavioural analysis of Myshkin mice revealed phenotypic abnormalities similar to symptoms of AHC, including motor dysfunction and cognitive impairment. 2-DG imaging of Myshkin mice identified compromised thalamocortical functioning that includes a deficit in frontal cortex functioning (hypofrontality), directly mirroring that reported in AHC, along with reduced thalamocortical functional connectivity. Our results thus provide validation for missense mutations in Na+,K+-ATPase α3 as a cause of AHC, and highlight Myshkin mice as a starting point for the exploration of disease mechanisms and novel treatments in AHC.
Myshkin mice heterozygous for an inactivating mutation in the neuron‐specific Na+,K+‐ATPase α3 isoform show behavior analogous to mania, including an abnormal endogenous circadian period. Agrin is a proteoglycan implicated as a regulator of synapses that has been proposed to inhibit activity of Na+,K+‐ATPase α3. We examined whether the mania‐related behavior of Myshkin mice could be rescued by a reduction in the expression of agrin through genetic knockout. The suppression of agrin reduced hyperambulation and holeboard exploration, restored anxiety‐like behavior (or reduced risk‐taking behavior), improved prepulse inhibition and shortened the circadian period. Hence, agrin is important for regulating mania‐like behavior and circadian rhythms. In Myshkin mice, the suppression of agrin increased brain Na+,K+‐ATPase activity by 11 ± 4%, whereas no effect on Na+,K+‐ATPase activity was detected when agrin was suppressed in mice without the Myshkin mutation. These results introduce agrin as a potential therapeutic target for the treatment of mania and other neurological disorders associated with reduced Na+,K+‐ATPase activity and neuronal hyperexcitability.